Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsHemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis diseaseRecruitingPhase 12026-04-17NCT06034002

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Incyte Corporation153

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
City of Hope Medical CenterDuarteUnited States313
Cleveland ClinicClevelandUnited States558
Dana Farber Cancer InstituteBostonUnited States300
Icahn School of Medicine at Mount SinaiNew YorkUnited States342
Johns Hopkins HospitalBaltimoreUnited States135
MD Anderson Cancer CenterHoustonUnited States589
Memorial Sloan Kettering Cancer CenterNew YorkUnited States1000
Stanford Cancer InstitutePalo AltoUnited States21
The University of Kansas Cancer CenterWestwoodUnited States31
University of Miami Health SystemMiamiUnited States13
Vanderbilt University Medical CenterNashvilleUnited States427
Wake Forest Baptist Medical CenterWinston-SalemUnited States25
Washington University School of MedicineSt LouisUnited States26